Calprotectin--a novel marker of obesity.

<h4>Background</h4>The two inflammatory molecules, S100A8 and S100A9, form a heterodimer, calprotectin. Plasma calprotectin levels are elevated in various inflammatory disorders. We hypothesized that plasma calprotectin levels would be increased in subjects with low-grade systemic inflam...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ole Hartvig Mortensen, Anders Rinnov Nielsen, Christian Erikstrup, Peter Plomgaard, Christian Philip Fischer, Rikke Krogh-Madsen, Birgitte Lindegaard, Anne Marie Petersen, Sarah Taudorf, Bente Klarlund Pedersen
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2009
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/d4414ab96a72494ab4f2a07471bfe9eb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d4414ab96a72494ab4f2a07471bfe9eb
record_format	dspace
spelling	oai:doaj.org-article:d4414ab96a72494ab4f2a07471bfe9eb2021-11-25T06:28:48ZCalprotectin--a novel marker of obesity.1932-620310.1371/journal.pone.0007419https://doaj.org/article/d4414ab96a72494ab4f2a07471bfe9eb2009-10-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19823685/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>The two inflammatory molecules, S100A8 and S100A9, form a heterodimer, calprotectin. Plasma calprotectin levels are elevated in various inflammatory disorders. We hypothesized that plasma calprotectin levels would be increased in subjects with low-grade systemic inflammation i.e. either obese subjects or subjects with type 2 diabetes.<h4>Methodology/principal findings</h4>Plasma calprotectin and skeletal muscle S100A8 mRNA levels were measured in a cohort consisting of 199 subjects divided into four groups depending on presence or absence of type 2 diabetes (T2D), and presence or absence of obesity. There was a significant interaction between obesity and T2D (p = 0.012). Plasma calprotectin was increased in obese relative to non-obese controls (p<0.0001), whereas it did not differ between obese and non-obese patients with T2D (p = 0.62). S100A8 mRNA levels in skeletal muscle were not influenced by obesity or T2D. Multivariate regression analysis (adjusting for age, sex, smoking and HOMA2-IR) showed plasma calprotectin to be strongly associated with BMI, even when further adjusted for fitness, CRP, TNF-alpha or neutrophil number.<h4>Conclusions/significance</h4>Plasma calprotectin is a marker of obesity in individuals without type 2 diabetes.Ole Hartvig MortensenAnders Rinnov NielsenChristian ErikstrupPeter PlomgaardChristian Philip FischerRikke Krogh-MadsenBirgitte LindegaardAnne Marie PetersenSarah TaudorfBente Klarlund PedersenPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 4, Iss 10, p e7419 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ole Hartvig Mortensen Anders Rinnov Nielsen Christian Erikstrup Peter Plomgaard Christian Philip Fischer Rikke Krogh-Madsen Birgitte Lindegaard Anne Marie Petersen Sarah Taudorf Bente Klarlund Pedersen Calprotectin--a novel marker of obesity.
description	<h4>Background</h4>The two inflammatory molecules, S100A8 and S100A9, form a heterodimer, calprotectin. Plasma calprotectin levels are elevated in various inflammatory disorders. We hypothesized that plasma calprotectin levels would be increased in subjects with low-grade systemic inflammation i.e. either obese subjects or subjects with type 2 diabetes.<h4>Methodology/principal findings</h4>Plasma calprotectin and skeletal muscle S100A8 mRNA levels were measured in a cohort consisting of 199 subjects divided into four groups depending on presence or absence of type 2 diabetes (T2D), and presence or absence of obesity. There was a significant interaction between obesity and T2D (p = 0.012). Plasma calprotectin was increased in obese relative to non-obese controls (p<0.0001), whereas it did not differ between obese and non-obese patients with T2D (p = 0.62). S100A8 mRNA levels in skeletal muscle were not influenced by obesity or T2D. Multivariate regression analysis (adjusting for age, sex, smoking and HOMA2-IR) showed plasma calprotectin to be strongly associated with BMI, even when further adjusted for fitness, CRP, TNF-alpha or neutrophil number.<h4>Conclusions/significance</h4>Plasma calprotectin is a marker of obesity in individuals without type 2 diabetes.
format	article
author	Ole Hartvig Mortensen Anders Rinnov Nielsen Christian Erikstrup Peter Plomgaard Christian Philip Fischer Rikke Krogh-Madsen Birgitte Lindegaard Anne Marie Petersen Sarah Taudorf Bente Klarlund Pedersen
author_facet	Ole Hartvig Mortensen Anders Rinnov Nielsen Christian Erikstrup Peter Plomgaard Christian Philip Fischer Rikke Krogh-Madsen Birgitte Lindegaard Anne Marie Petersen Sarah Taudorf Bente Klarlund Pedersen
author_sort	Ole Hartvig Mortensen
title	Calprotectin--a novel marker of obesity.
title_short	Calprotectin--a novel marker of obesity.
title_full	Calprotectin--a novel marker of obesity.
title_fullStr	Calprotectin--a novel marker of obesity.
title_full_unstemmed	Calprotectin--a novel marker of obesity.
title_sort	calprotectin--a novel marker of obesity.
publisher	Public Library of Science (PLoS)
publishDate	2009
url	https://doaj.org/article/d4414ab96a72494ab4f2a07471bfe9eb
work_keys_str_mv	AT olehartvigmortensen calprotectinanovelmarkerofobesity AT andersrinnovnielsen calprotectinanovelmarkerofobesity AT christianerikstrup calprotectinanovelmarkerofobesity AT peterplomgaard calprotectinanovelmarkerofobesity AT christianphilipfischer calprotectinanovelmarkerofobesity AT rikkekroghmadsen calprotectinanovelmarkerofobesity AT birgittelindegaard calprotectinanovelmarkerofobesity AT annemariepetersen calprotectinanovelmarkerofobesity AT sarahtaudorf calprotectinanovelmarkerofobesity AT benteklarlundpedersen calprotectinanovelmarkerofobesity
_version_	1718413712571760640

Calprotectin--a novel marker of obesity.

Ejemplares similares